Odevixibat-13C6
Product Specifications
UNSPSC Description
Odevixibat-13C6 is 13C labeled Odevixibat (HY-109120). Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis[1].
Target Antigen
Apical Sodium-Dependent Bile Acid Transporter; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
Membrane Transporter/Ion Channel;Others
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/odevixibat-13c6.html
Solubility
10 mM in DMSO
Smiles
CCCCC(CCCC)(NS(=O)(C1=CC(OCC(N[C@H](C2=CC=C(C=C2)O)C(N[C@H](C(O)=O)CC)=O)=O)=C(C=C13)SC)=O)CN3[13C]4=[13CH][13CH]=[13CH][13CH]=[13CH]4
Molecular Weight
746.88
References & Citations
[1]Baghdasaryan A, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.J Hepatol. 2016 Mar;64(3):674-81.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-109120S1/Odevixibat-13C6-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-109120S1/
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
